The objectives of this study are to evaluate the absolute bioavailability, and absorption and excretion of DA-1229, an IMP in clinical assessment for the treatment of T2DM. The oral and IV PK of DA-1229 will also be evaluated. The metabolism of DA-1229 may also be evaluated.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Enrollment
12
Quotient Clinical
Nottingham, Ruddington, United Kingdom
the absolute bioavailability of DA-1229 (F)
Time frame: 240 hours
The mass balance recovery (Ae, %Ae)
Time frame: 240 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.